Research Institute, Femtobiomed Co., Ltd., 700, Pangyo-ro, Seongnam-si, Gyeonggi-do 13516, Korea.
Department of Mechanical System Engineering, Korea Polytechnic Univsersity, 237 Sangidaehak-ro, Siheung-si, Gyoenggi-do 15073, Korea.
Int J Mol Sci. 2017 Nov 7;18(11):2348. doi: 10.3390/ijms18112348.
In general, a drug candidate is evaluated using 2D-cultured cancer cells followed by an animal model. Despite successful preclinical testing, however, most drugs that enter human clinical trials fail. The high failure rates are mainly caused by incompatibility between the responses of the current models and humans. Here, we fabricated a cancer microtissue array in a multi-well format that exhibits heterogeneous and batch-to-batch structure by continuous deposition of collagen-suspended Hela cells on a fibroblast-layered nanofibrous membrane via inkjet printing. Expression of both Matrix Metalloproteinase 2 (MMP2) and Matrix Metalloproteinase 9 (MMP9) was higher in cancer microtissues than in fibroblast-free microtissues. The fabricated microtissues were treated with an anticancer drug, and high drug resistance to doxorubicin occurred in cancer microtissues but not in fibroblast-free microtissues. These results introduce an inkjet printing fabrication method for cancer microtissue arrays, which can be used for various applications such as early drug screening and gradual 3D cancer studies.
通常情况下,药物候选物会先在 2D 培养的癌细胞中进行评估,然后再在动物模型中进行评估。然而,尽管临床前测试取得了成功,但大多数进入人体临床试验的药物都失败了。高失败率主要是由于当前模型与人类的反应不一致造成的。在这里,我们通过喷墨打印将悬浮有胶原的 Hela 细胞连续沉积在成纤维细胞层状纳米纤维膜上,在多孔板中制造了具有异质和批间结构的癌症微组织阵列。与无成纤维细胞的微组织相比,癌症微组织中基质金属蛋白酶 2(MMP2)和基质金属蛋白酶 9(MMP9)的表达更高。用抗癌药物处理所制备的微组织,发现癌症微组织对阿霉素的耐药性很高,但无成纤维细胞的微组织没有。这些结果介绍了一种用于癌症微组织阵列的喷墨打印制造方法,可用于早期药物筛选和逐步的 3D 癌症研究等各种应用。